卡那奴单抗抗炎治疗预防心力衰竭住院
在既往心肌梗死且高敏C反应蛋白≥2 mg/L的患者中,随机双盲安慰剂对照试验显示,白细胞介素-1β抑制剂卡那奴单抗呈剂量依赖性降低心力衰竭住院及心力衰竭住院或心衰相关死亡的复合终点,但各剂量组风险比置信区间多含1,趋势检验有统计学意义。
要点
- 卡那奴单抗300 mg每3月皮下注射与心衰住院风险降低相关,但95%CI上限接近1。
- 复合终点(心衰住院或心衰相关死亡)也呈剂量依赖性降低趋势。
- 基线高敏C反应蛋白较高者后续心衰住院风险更高。
核心结论
- 在既往心肌梗死且高敏C反应蛋白≥2 mg/L的患者中,卡那奴单抗与心力衰竭住院及心力衰竭住院或心衰相关死亡复合终点的剂量依赖性降低相关。
研究设计与样本
- 基线时2173例(22%)报告有心力衰竭病史,中位随访3.7年。
主要发现
- 随访期间共385例发生心力衰竭住院事件。
- 发生心衰住院者基线高敏C反应蛋白中位数(四分位间距)为5.7(3.5, 9.9)mg/L,未发生者为4.2(2.8, 6.9)mg/L,P<0.0001。
- 与安慰剂相比,卡那奴单抗50 mg、150 mg、300 mg的心衰住院未校正风险比分别为1.04(95%CI 0.79-1.36)、0.86(95%CI 0.65-1.13)、0.76(95%CI 0.57-1.01),趋势P=0.025。
- 心衰住院或心衰相关死亡复合终点的未校正风险比分别为1.00(95%CI 0.78-1.29)、0.88(95%CI 0.68-1.13)、0.78(95%CI 0.60-1.02),趋势P=0.042。
临床怎么用
- 对于既往心肌梗死且高敏C反应蛋白升高(≥2 mg/L)的患者,卡那奴单抗可能有助于降低心衰住院风险,但需注意各剂量组风险比置信区间均包含1,证据尚不足以推荐常规使用。
局限性
- 原文未明确报告预设主要终点的校正分析或亚组分析结果。
- 心衰住院为前瞻性收集的终点,但原文未说明其是否为主要终点或次要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subclinical inflammation is associated with an increased risk of heart failure and with adverse prognosis in patients with established heart failure. Yet, treatments specifically directed at reducing inflammation in patients with heart failure have not yet shown improved clinical outcomes. We tested the hypothesis that the interleukin-1β inhibitor canakinumab would prevent hospitalization for heart failure (HHF) and the composite of HHF or heart failure-related mortality. METHODS: We randomized 10 061 patients with prior myocardial infarction and high-sensitivity C-reactive protein ≥2 mg/L to canakinumab 50, 150, or 300 mg or placebo, given subcutaneously once every 3 months. In total, 2173 (22%) reported a history of heart failure at baseline. We tested the hypothesis that canakinumab prevents prospectively collected HHF events and the composite of HHF or heart failure-related mortality. RESULTS: A total of 385 patients had an HHF event during a median follow-up of 3.7 years. Patients who had HHF were older, had higher body mass index, and were more likely to have diabetes mellitus, hypertension, and prior coronary bypass surgery. As anticipated, median (quartile 1, 3) baseline concentrations of high-sensitivity C-reactive protein were higher among those who had HHF during follow-up than those who did not (5.7 [3.5, 9.9] mg/L versus 4.2 [2.8, 6.9] mg/L, respectively; P<0.0001). The unadjusted hazard ratios for HHF with each dose of canakinumab compared with placebo were 1.04 (95% CI, 0.79-1.36) for 50 mg, 0.86 (95% CI, 0.65-1.13) for 150 mg, and 0.76 (95% CI, 0.57-1.01) for 300 mg ( P for trend=0.025). The composite of HHF or heart failure-related mortality was also reduced by canakinumab, with unadjusted hazard ratios of 1.00 (95% CI, 0.78-1.29) for 50 mg, 0.88 (95% CI, 0.68-1.13) for 150 mg, and 0.78 (95% CI, 0.60-1.02) for 300 mg ( P for trend=0.042). CONCLUSIONS: These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an interleukin-1β inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or heart failure-related mortality in a population of patients with prior myocardial infarction and elevations in high-sensitivity C-reactive protein. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01327846.
引用
- Everett BM, Cornel JH, Lainscak M, et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019. PMID: 30586730. doi:10.1161/CIRCULATIONAHA.118.038010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。